Price range: £120.08 through £326.46

SKU 5-AMINO Category

5-Amino-1MQ is a 5-Amino-1MQ peptide formulated for laboratory research involving nicotinamide N-methyltransferase (NNMT) pathways. Researchers use this compound to study how blocking NNMT affects cellular metabolism, NAD⁺ balance, and methylation-related signaling. Because the 5-Amino-1MQ peptide acts directly on enzyme targets linked to metabolic control, it supports precise mechanistic studies under controlled experimental conditions.

Scientists value 5-Amino-1MQ for its role in investigations into energy homeostasis, adipocyte biology, and downstream effects of enhanced NAD⁺ availability. It enables researchers to examine how NNMT inhibition can influence mitochondrial output, metabolic flexibility, and intracellular stress responses. In addition, the 5-Amino-1MQ peptide allows direct comparisons with other NAD⁺-supporting research compounds to better understand pathway specificity and bioenergetic outcomes.

Research teams frequently select 5-Amino-1MQ for:

  • Analysing NNMT-driven metabolic signaling

  • Studying NAD⁺-linked energy regulation in vitro

  • Mapping methylation and enzyme-inhibition effects

  • Comparing targeted metabolic inhibitors in controlled models

Because this compound provides consistent, well-characterized activity, it supports reproducible research requiring clear dose-response interpretation, reliable timing, and traceable experimental inputs. These properties make the 5-Amino-1MQ peptide suitable for advanced metabolic, enzymology, and cellular-bioenergetic studies.

Our 5-Amino-1MQ peptide is supplied as a high-purity laboratory reagent intended solely for qualified scientific professionals. It is not approved for clinical, therapeutic, diagnostic, or veterinary use. All handling must follow appropriate institutional safety protocols and regulatory standards for investigational metabolic compounds.

For research use only. Not for human consumption.

COA Request

GET 10% OFF

Recieve product and research updates through our newsletter